Search

everythinglearnresearchcommunity

for

Search:↓

Some patients may experience lasting sexual dysfunction, depression, and other side effects from 5α-reductase inhibitor therapy.

5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.

New compounds were made that are promising for prostate cancer therapy.

A plant extract was found to effectively block an enzyme related to male hormone-related diseases.

Four new compounds were more effective than finasteride in treating prostate issues and hair loss, with one being 100 times more active and safe for use.

Certain derivatives are more effective 5α-reductase type 2 inhibitors than finasteride.

Inhibiting 5α-reductase can help reduce prostate cancer risk and improve treatment.

A brominated phenoxy compound effectively inhibits a human enzyme and shows potential for clinical use.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Modified steroidal inhibitors showed promise in treating hormone-dependent cancers.

MK-0773 is a moderate inhibitor of the SRD5A2 enzyme.

FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.

Medications for hair loss and prostate issues can significantly increase the risk of sexual side effects and other negative symptoms.

5-ARI therapy may help prevent prostate cancer progression.

Men on 5-alpha-reductase inhibitors might have worse COVID-19 outcomes.

5-alpha-reductase inhibitors can effectively treat benign prostatic hyperplasia.

5α-reductase inhibitors may help with prostate cancer but could increase the risk of severe tumors, so careful use is advised.

Starting 5-alpha reductase inhibitors does not significantly increase the risk of rhabdomyolysis in older men, but is linked to a higher risk of muscle conditions.

Three specific 4-azasteroid-2-oximes showed strong enzyme inhibition, but less than finasteride.

Certain medications, especially 5-alpha reductase inhibitors, are commonly linked to erectile dysfunction.

5-alpha-reductase inhibitors may help stabilize or slow down hair loss in some frontal fibrosing alopecia patients, but more research is needed to confirm their effectiveness and safety.

Treatment with 5α-reductase inhibitors is linked to a delay in prostate cancer diagnosis and may affect survival rates.

Finasteride and dutasteride may cause metabolic issues like liver disease and diabetes.

Inhibitors of the enzyme 5 alpha-reductase could potentially treat disorders like prostate cancer and baldness.

Combining α1A-blockers with Prozac is more effective for treating premature ejaculation than Prozac alone.

Combination therapy with fesoterodine and doxazosin improves bladder function and delays BPH progression.

Patients with mood disorders using 5α-reductase inhibitors may have a higher risk of suicidal thoughts.

5-alpha reductase inhibitors may cause sexual side effects, breast complications, and other health risks in men with hair loss.